first report of a case of pneumococcal meningitis which did not respond to the ceftriaxone therapy despite the isolated organism being sensitive to this antibiotic in vitro
Clicks: 249
ID: 150268
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
249 views
35 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #10 of 21 articles by views in novelty in biomedicine
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
A 60-year-old man presented with pneumococcal meningitis which did not respond to the ceftriaxone therapy, in spite of in-vitro susceptibility (minimal inhibitory concentration of 0.016 μg/dLit) of the isolated organism to this antibacterial agent, although ceftriaxone is still the drug of choice for such pneumococcal meningitis. Review of published articles revealed no report of clinical resistance in organisms which were susceptible to the same antimicrobial agent in vitro. This alarming emergence of isolates with in vivo resistance should be considered and even could lead to a shift in the empirical antibiotic therapy for pneumococcal infections.
| Reference Key |
mojtabavi2011casefirst
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Maryam Mojtabavi;Hamid Reza Naderi;Ashraf Tavanaee Sani;Mahmood Bagheri;Kiarash Ghazvini |
| Journal | novelty in biomedicine |
| Year | 2011 |
| DOI |
10.1155/2011/485952
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.